Graincide Tablet SR is a combination medication containing Propranolol 40 mg and Flunarizine 10 mg, formulated for sustained release to provide prolonged therapeutic effects. Propranolol is a non-selective beta-adrenergic blocker that reduces heart rate, myocardial contractility, and blood pressure, thereby decreasing cardiac workload and oxygen demand. It is commonly used in the management of hypertension, angina pectoris, arrhythmias, and prevention of migraine. Flunarizine is a calcium channel blocker with antihistaminic properties, effective in the prophylaxis of migraine and treatment of vertigo by inhibiting calcium influx into vascular smooth muscle and neurons, stabilizing neuronal excitability. The combination of these two agents in Graincide Tablet SR offers a dual approach in the prevention of migraine headaches, addressing both vascular and neurological components. This medication is indicated for patients requiring long-term migraine prophylaxis, especially those with concurrent cardiovascular conditions benefiting from beta-blockade. Graincide Tablet SR should be administered as directed by a healthcare professional, with caution advised in patients with asthma, bradycardia, hypotension, or hepatic impairment. Common side effects may include fatigue, dizziness, gastrointestinal disturbances, and cold extremities. Regular monitoring is recommended to assess therapeutic response and detect potential adverse effects.